Blair William & Co. IL lessened its stake in shares of Eli Lilly And Co (NYSE:LLY) by 7.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 312,042 shares of the company’s stock after selling 23,412 shares during the period. Blair William & Co. IL’s holdings in Eli Lilly And Co were worth $43,286,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Moody Lynn & Lieberson LLC purchased a new position in Eli Lilly And Co during the 1st quarter valued at about $15,713,000. Bank of New York Mellon Corp grew its stake in Eli Lilly And Co by 1.4% during the 4th quarter. Bank of New York Mellon Corp now owns 8,125,931 shares of the company’s stock valued at $1,067,990,000 after acquiring an additional 111,832 shares in the last quarter. Carnegie Capital Asset Management LLC grew its stake in Eli Lilly And Co by 22.1% during the 4th quarter. Carnegie Capital Asset Management LLC now owns 6,386 shares of the company’s stock valued at $839,000 after acquiring an additional 1,158 shares in the last quarter. Nikulski Financial Inc. purchased a new position in Eli Lilly And Co during the 4th quarter valued at about $210,000. Finally, Investment House LLC grew its stake in Eli Lilly And Co by 2.1% during the 4th quarter. Investment House LLC now owns 42,140 shares of the company’s stock valued at $5,538,000 after acquiring an additional 865 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.
Shares of LLY stock traded down $1.12 during trading hours on Friday, reaching $151.16. 2,322,495 shares of the company’s stock were exchanged, compared to its average volume of 2,875,585. Eli Lilly And Co has a fifty-two week low of $101.36 and a fifty-two week high of $164.90. The stock has a market capitalization of $145.65 billion, a P/E ratio of 24.99, a P/E/G ratio of 1.82 and a beta of 0.25. The business has a fifty day moving average price of $152.85 and a 200-day moving average price of $136.00. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 4.37.
Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 23rd. The company reported $1.75 EPS for the quarter, topping analysts’ consensus estimates of $1.48 by $0.27. Eli Lilly And Co had a return on equity of 194.18% and a net margin of 23.97%. The company had revenue of $5.86 billion during the quarter, compared to analyst estimates of $5.48 billion. During the same period in the previous year, the company earned $1.33 earnings per share. The company’s quarterly revenue was up 15.1% compared to the same quarter last year. As a group, research analysts expect that Eli Lilly And Co will post 6.81 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a dividend of $0.74 per share. The ex-dividend date is Thursday, May 14th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.96%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 49.01%.
Several equities research analysts recently commented on the company. Cantor Fitzgerald boosted their price target on Eli Lilly And Co from $156.00 to $185.00 and gave the company an “overweight” rating in a research note on Friday, April 24th. UBS Group cut Eli Lilly And Co from a “buy” rating to a “neutral” rating and boosted their price target for the company from $157.00 to $158.00 in a research note on Monday, April 20th. Mizuho boosted their price target on Eli Lilly And Co from $148.00 to $155.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Barclays assumed coverage on Eli Lilly And Co in a research note on Thursday, February 27th. They issued an “overweight” rating for the company. Finally, Cowen boosted their price target on Eli Lilly And Co from $145.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $158.64.
In related news, major shareholder Lilly Endowment Inc sold 12,663 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $163.60, for a total value of $2,071,666.80. Following the completion of the transaction, the insider now directly owns 112,197,641 shares in the company, valued at $18,355,534,067.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Myles O’neill sold 25,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $140.15, for a total value of $3,503,750.00. Following the completion of the transaction, the senior vice president now owns 44,773 shares of the company’s stock, valued at $6,274,935.95. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 906,320 shares of company stock valued at $132,984,238. Corporate insiders own 0.09% of the company’s stock.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: What are the components of an earnings report?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.